Abstract
Three nitrosourea derivatives have been shown to be active against malignant brain glioma. The EORTC Brain Tumor Group is concerned with the therapeutic effects of one of them — CCNU (1-2-chloroethyl-3-cyclohexyl-l-nitro-sourea) — on three clinical parameters; total survival time, objective remission rates and free interval between surgery and relapse. To meet the difficulties encountered in measuring these different criteria two parallel trials uere performed. The aim of trial 26741 was to study the rate of objective remissions and free interval, the purpose of trial 26742 was to measure the effect of CCNU on survival time.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1976 Plenum Press, New York
About this chapter
Cite this chapter
EORTC Brain Tumor Group, presented by L.Calliauw. (1976). Effect of CCNU on Survival, Objective Remissions and Free Interval in Patients with Malignant Gliomas. In: Hellmann, K., Connors, T.A. (eds) Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-4349-3_31
Download citation
DOI: https://doi.org/10.1007/978-1-4613-4349-3_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4351-6
Online ISBN: 978-1-4613-4349-3
eBook Packages: Springer Book Archive